Di Yi Cai Jing·2025-12-19 02:38Group 1 - The core announcement is the appointment of Dr. Wang Lai as the new President and Global Head of R&D at BeiGene, effective December 17, 2025, which has sparked market speculation [2][3] - Prior to this, the only President of BeiGene was Wu Xiaobin, who also served as the Chief Operating Officer. Dr. Wang was previously the Senior Vice President and Global Head of R&D [3] - With Dr. Wang's new role, there is speculation about potential changes to Wu Xiaobin's position, but internal sources confirmed that Wu will retain his roles and responsibilities [3] Group 2 - Dr. Wang is recognized as a key figure in the company, having led the development of the BTK inhibitor, Zebrutinib, which is projected to generate $2.6 billion in sales in 2024, ranking 20th globally among anti-cancer drugs [3] - The success of Zebrutinib is attributed to both its therapeutic breakthroughs and effective commercialization, showcasing the strong collaboration between Dr. Wang's R&D team and Wu Xiaobin's commercialization team [3][4] - The company is now entering a dual-presidency phase with both Dr. Wang and Wu Xiaobin in leadership roles [4]